Receive our newsletter – data, insights and analysis delivered to you
July 20, 2009

Mylan Receives Additional Strength Approval for Antipsychotic Haloperidol

Mylan Pharmaceuticals has received approval from the US Food and Drug Administration (FDA) for additional-strength antipsychotic Haloperidol tablets. Haloperidol tablets are an antipsychotic typically used to reduce the symptoms of schizophrenia and outbursts associated with Tourette sy

By cms admin

Mylan Pharmaceuticals has received approval from the US Food and Drug Administration (FDA) for additional-strength antipsychotic Haloperidol tablets.

Haloperidol tablets are an antipsychotic typically used to reduce the symptoms of schizophrenia and outbursts associated with Tourette syndrome.

Mylan received approval from the FDA for the tablets in 10mg and 20mg form in addition to Mylan’s currently marketed 0.5mg, 1mg, 2mg and 5mg strengths of the product.

Related Companies

Content from our partners
Extractables and leachables analysis in pharmaceutical quality control
How Hengst helped to keep Germany’s charity “star singers” shining
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU